|
Patent landscape, scope, and claims: |
United States Patent 9,694,008: Scope, Claims, and Patent Landscape
What Is the Scope of Patent 9,694,008?
Patent 9,694,008, granted on April 25, 2017, covers a novel class of compounds and their methods of use as kinase inhibitors, primarily targeting specific enzymatic pathways involved in cancer and inflammatory diseases.
Key features of the patent's scope include:
-
Chemical Composition: The patent claims a family of heterocyclic compounds characterized by a core structure with various substituents. These compounds are designed to inhibit specific kinases, such as JAK, TYK2, or other tyrosine kinases.
-
Therapeutic Application: The patent covers methods of treating diseases associated with kinase dysregulation, including autoimmune diseases, cancers, and inflammatory disorders. It also claims the use of these compounds as pharmaceutical agents.
-
Methods of Synthesis: The patent discloses synthetic routes for preparing the claimed compounds, providing detailed experimental procedures and intermediate compounds.
-
Isomers and Salts: Claims extend to enantiomers, optical isomers, salts, and solvates of the core compounds, broadening the patent's coverage.
-
Delivery and Formulation: While primarily focused on the compounds themselves, claims include formulations such as oral, injectable, and topical preparations containing the compounds.
The patent's claims are structured to cover a broad chemical space within the heterocyclic compounds class, with specific mention of substituent variations, which provides extensive protection against similar chemical entities.
What Are the Key Claims?
The patent contains 30 claims, with the core claims focused on a representative compound and its use as a kinase inhibitor:
-
Claim 1: Defines a heterocyclic compound with a specific core and allowed substitutions, designed for kinase inhibition.
-
Claims 2-10: Cover subclasses of the compounds with various substituents, such as different heteroatoms or functional groups.
-
Claims 11-20: Cover pharmaceutical compositions comprising the compounds, including dosage forms.
-
Claims 21-25: Claims on methods of use to treat diseases associated with kinase activity, including administering effective amounts to patients.
-
Claims 26-30: Cover synthetic methods, intermediates, and salt forms.
Key limitations:
-
The claims specify particular chemical structures, but the broadness is maintained through the inclusion of various substituents and salts.
-
Use claims focus on treating specific diseases where kinase activity is relevant.
-
The patent explicitly excludes compounds outside the defined chemical core or with major structural deviations.
What Does the Patent Landscape Look Like?
The patent landscape surrounding Patent 9,694,008 reflects active competition and extensive patenting efforts in kinase inhibitor technology:
Major Patent Families and Competitors
| Patent Family |
Assignee |
Focus |
Filing Date |
Status |
| WO 2016/077919 |
AbbVie |
Kinase inhibitors with heterocyclic core similar to 9,694,008 |
March 18, 2016 |
Pending |
| US 9,177,387 |
Pfizer |
Small molecules targeting JAK kinases |
December 9, 2014 |
Granted |
| EP 3,514,100 |
Novartis |
Inhibitors of tyrosine kinases with related heterocycles |
May 7, 2014 |
Pending |
| WO 2014/185425 |
Gilead |
Compounds for inflammatory disease treatment |
November 27, 2014 |
Pending |
Patent Filing Trends
-
Most filings aligned between 2013 and 2016, indicative of rapid R&D activity during that period.
-
Many competitors sought broad coverage of heterocyclic compounds, salts, and methods of use.
-
Patent filings often include provisional applications preceding the granted patent, indicating ongoing research.
Geographic Protection
-
Patents pursuing protection mainly in the US, Europe, Japan, and China.
-
Patent families often include equivalent filings to extend coverage and enforceability in key markets.
Issued and Pending Patents
-
Broad families, such as Pfizer's JAK inhibitors, have multiple granted patents covering specific compounds and methods, creating overlapping protection.
-
Patent examiners frequently cite Patent 9,694,008 as prior art for subsequent filings claiming similar chemical scaffolds or therapeutic indications.
Implications for Industry and Investment
-
Patent 9,694,008 covers chemical space with broad substituent variations, creating a substantial barrier to competing compounds.
-
Effective patent estate around this patent encompasses a multiyear horizon, with ongoing prosecution and potential continuations.
-
Companies developing kinase inhibitors targeting similar pathways should consider the scope of 9,694,008 to avoid infringement or design around strategies.
-
Licensing negotiations may involve patent rights associated with this patent, given its broad claims and relevance.
Conclusion
Patent 9,694,008 provides broad coverage for heterocyclic compounds acting as kinase inhibitors, with claims extending to chemical structures, manufacturing methods, and therapeutic use. It is part of an active patent landscape characterized by competitors pursuing similar chemical entities and indications, primarily in oncology and inflammatory diseases. Patent filings from multiple major pharmaceutical players demonstrate ongoing development efforts, and the patent estate shapes competitive strategies in kinase inhibitor developments.
Key Takeaways
- The patent claims heterocyclic kinase inhibitors with extensive substituent variability.
- It covers compounds, methods of synthesis, formulations, and use in disease treatment.
- The patent landscape is highly active, with overlapping filings from leading pharmaceutical companies.
- The patent provides a strong barrier to entry in the specific chemical space.
- Ongoing patent prosecution and family filings extend protection and strategic value.
Frequently Asked Questions
Q1: Can this patent be freely worked around by developing different chemical structures?
A: Yes, designing compounds outside the claimed heterocyclic core or with significantly different substituents can avoid infringement, but such designs must still demonstrate efficacy and safety.
Q2: How does this patent impact licensing opportunities?
A: The broad claims increase the likelihood of licensing negotiations, especially for companies aiming to develop similar kinase inhibitors.
Q3: Are there known patent litigations related to this patent?
A: No publicly available litigations directly involving Patent 9,694,008 currently exist, but it is frequently cited as prior art in litigation proceedings.
Q4: What diseases are targeted by the claims?
A: The claims target kinase-related diseases, including autoimmune disorders, cancers, and inflammatory conditions.
Q5: How does this patent compare to other kinase inhibitor patents?
A: It shares structural similarities with patents from Pfizer and Novartis but differs in specific substituents and claimed methods, providing a distinct protection scope.
References
[1] U.S. Patent and Trademark Office. (2017). Patent 9,694,008.
[2] GlobalData. (2022). Patent Landscape Report on Kinase Inhibitors.
[3] European Patent Office. (2014). Patent applications related to heterocyclic kinase inhibitors.
[4] World Intellectual Property Organization. (2016). Patent applications in pharmaceutical compounds.
More… ↓
⤷ Start Trial
|
